Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs neostigmine for reversal of rocuronium/vecuronium block at T2 reappearance
2005-001135-30Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Sep 2005
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Sugammadex (4 arms), sponsored by Organon & Co. Primary endpoint: Time to recovery of T4/T1 ratio to 0.9. Started Sep 2005; status: completed.
02
Drugs
Sugammadex
Beyond the preview
Go deeper on 2005-001135-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001135-30.